These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 28469644)
1. The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease. Kinghorn KJ; Asghari AM; Castillo-Quan JI Neural Regen Res; 2017 Mar; 12(3):380-384. PubMed ID: 28469644 [TBL] [Abstract][Full Text] [Related]
2. A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin. Kinghorn KJ; Grönke S; Castillo-Quan JI; Woodling NS; Li L; Sirka E; Gegg M; Mills K; Hardy J; Bjedov I; Partridge L J Neurosci; 2016 Nov; 36(46):11654-11670. PubMed ID: 27852774 [TBL] [Abstract][Full Text] [Related]
3. The relationship between glucocerebrosidase mutations and Parkinson disease. Migdalska-Richards A; Schapira AH J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875 [TBL] [Abstract][Full Text] [Related]
4. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease. Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535 [TBL] [Abstract][Full Text] [Related]
12. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146 [TBL] [Abstract][Full Text] [Related]
13. Glucocerebrosidase Defects as a Major Risk Factor for Parkinson's Disease. Avenali M; Blandini F; Cerri S Front Aging Neurosci; 2020; 12():97. PubMed ID: 32372943 [TBL] [Abstract][Full Text] [Related]
15. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease. Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292 [TBL] [Abstract][Full Text] [Related]
16. Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagy. Kuo SH; Tasset I; Cheng MM; Diaz A; Pan MK; Lieberman OJ; Hutten SJ; Alcalay RN; Kim S; Ximénez-Embún P; Fan L; Kim D; Ko HS; Yacoubian T; Kanter E; Liu L; Tang G; Muñoz J; Sardi SP; Li A; Gan L; Cuervo AM; Sulzer D Sci Adv; 2022 Feb; 8(6):eabm6393. PubMed ID: 35138901 [TBL] [Abstract][Full Text] [Related]
17. Glitazone Treatment Rescues Phenotypic Deficits in a Fly Model of Gaucher/Parkinson's Disease. Shola-Dare O; Bailess S; Flores CC; Vanderheyden WM; Gerstner JR Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884544 [TBL] [Abstract][Full Text] [Related]
18. Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson's Disease: Pathogenesis and Therapeutic Implications. Zheng W; Fan D Front Aging Neurosci; 2022; 14():851135. PubMed ID: 35401150 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of cysteine protease cathepsin L increases the level and activity of lysosomal glucocerebrosidase. Kim MJ; Kim S; Reinheckel T; Krainc D JCI Insight; 2024 Feb; 9(3):. PubMed ID: 38329128 [TBL] [Abstract][Full Text] [Related]
20. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice. Rocha EM; Smith GA; Park E; Cao H; Graham AR; Brown E; McLean JR; Hayes MA; Beagan J; Izen SC; Perez-Torres E; Hallett PJ; Isacson O Antioxid Redox Signal; 2015 Aug; 23(6):550-64. PubMed ID: 26094487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]